Corium International Inc (CORI) Major Shareholder Perceptive Advisors Llc Acquires 50,350 Shares

Corium International Inc (NASDAQ:CORI) major shareholder Perceptive Advisors Llc acquired 50,350 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were bought at an average price of $11.83 per share, for a total transaction of $595,640.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Corium International Inc (CORI) traded up $0.78 during trading on Thursday, reaching $13.09. 660,735 shares of the company’s stock traded hands, compared to its average volume of 229,442. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. Corium International Inc has a 12-month low of $2.67 and a 12-month high of $13.24. The company has a market capitalization of $452.50, a PE ratio of -7.84 and a beta of 1.26.

Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. Corium International had a negative net margin of 149.99% and a negative return on equity of 482.64%. equities research analysts anticipate that Corium International Inc will post -1.47 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on CORI shares. Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Corium International in a research note on Friday, December 22nd. Needham & Company LLC boosted their price target on shares of Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. HC Wainwright set a $15.00 price target on shares of Corium International and gave the stock a “buy” rating in a research report on Friday, November 17th. Zacks Investment Research cut shares of Corium International from a “buy” rating to a “sell” rating in a research report on Tuesday, October 10th. Finally, Jefferies Group set a $10.00 price target on shares of Corium International and gave the stock a “buy” rating in a research report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Corium International has an average rating of “Buy” and an average target price of $12.86.

Hedge funds and other institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund acquired a new stake in Corium International during the 2nd quarter worth about $158,000. California State Teachers Retirement System acquired a new stake in Corium International during the 2nd quarter worth about $263,000. Teachers Advisors LLC acquired a new stake in Corium International during the 2nd quarter worth about $272,000. TIAA CREF Investment Management LLC acquired a new stake in Corium International during the 2nd quarter worth about $411,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in Corium International by 47.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock worth $476,000 after buying an additional 15,909 shares during the period. Hedge funds and other institutional investors own 89.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Corium International Inc (CORI) Major Shareholder Perceptive Advisors Llc Acquires 50,350 Shares” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/18/corium-international-inc-cori-major-shareholder-perceptive-advisors-llc-acquires-50350-shares.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply